PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Reports Provide an Insight on the Potential of Dyslipidemia Drugs in Key Emerging Markets - EMR’s latest publications provide an exceptional tool to understand the current trends, therapeutic structure, competitive landscape and the outlook for key emerging dyslipidemia drug markets till 2016
New Reports Provide an Insight on the Potential of Dyslipidemia Drugs in Key Emerging Markets

 

NewswireToday - /newswire/ - Noida, Uttar Pradesh, India, 2011/09/03 - EMR’s latest publications provide an exceptional tool to understand the current trends, therapeutic structure, competitive landscape and the outlook for key emerging dyslipidemia drug markets till 2016.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In its new series of reports on dyslipidemia, Expert Market Research, one of the world’s leading providers of lifescience market intelligence, analyses the market potential of dyslipidemia drugs in several key countries.

EMR’s dyslipidemia market series includes the following reports:
• Brazil Dyslipidemia Market Report and Forecast: 2011-2016
• Russia Dyslipidemia Market Report and Forecast: 2011-2016
• India Dyslipidemia Market Report and Forecast: 2011-2016
• China Dyslipidemia Market Report and Forecast: 2011-2016
• Mexico Dyslipidemia Market Report and Forecast: 2011-2016
• Greece Dyslipidemia Market Report and Forecast: 2011-2016
• Vietnam Dyslipidemia Market Report and Forecast: 2011-2016
• Egypt Dyslipidemia Market Report and Forecast: 2011-2016
• Indonesia Dyslipidemia Market Report and Forecast: 2011-2016
• Saudi Arabia Dyslipidemia Market Report and Forecast: 2011-2016
• South Africa Dyslipidemia Market Report and Forecast: 2011-2016
• Argentina Dyslipidemia Market Report and Forecast: 2011-2016
• Thailand Dyslipidemia Market Report and Forecast: 2011-2016
• South Korea Dyslipidemia Market Report and Forecast: 2011-2016
• Turkey Dyslipidemia Market Report and Forecast: 2011-2016

Each of these reports provide a comprehensive analysis of the current and future market trends in the dyslipidemia drugs market. These reports also facilitate a deep insight into the current and future epidemiology of dyslipidemia and its market structure besides probing into the performance of various therapeutic classes, companies, molecules and brands. These reports can serve as an excellent guide for clients who are in need of an in-depth understanding of the market for dyslipidemia drugs.

Key Questions Answered in this Report:
• What is the current and future size of the dyslipidemia patient population?
• What are the current and future prevalence rates for dyslipidemia?
• What has been the historical performance of the dyslipidemia market and how will it behave in the coming years?
• Who are the leading companies in the dyslipidemia market and how will they perform in the coming years?
• What has been the historical performance of various dyslipidemia therapeutic classes and how will they behave in the coming years?
• What are the leading molecules in the dyslipidemia market and how will they behave in the coming years?
• What are the key late stage pipeline drugs and how will they perform once they are launched?

Why should you buy this Report?
• To gain an in-depth insight into the prevalence of dyslipidemia.
• To have it as a powerful tool for identifying your target patient population.
• To facilitate business decision-making based on historical, current and forecast market data for dyslipidemia drugs.
• To identify potential classes, drugs, partners and competitors so as to develop strategies for market penetration and drug development.
• To develop business strategies by looking at companies those have been the biggest winners and losers in the dyslipidemia market.
• To gain an understanding into future market events and make more informed business decisions.

Research Objectives Achieved in this Report:
Evaluating the Epidemiology of Dyslipidemia:
Key Aspects Analyzed:
• Current and future prevalence of dyslipidemia.
• Current and future size of the patient pool.
Comprehensive Situation Analysis of the dyslipidemia Market:
Classes Covered: Statins, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators and all other Dyslipidemia drug classes
Key Aspects Analyzed:
• Historical, current and future market trends.
• Historical, current and future performance of various drugs.
• Historical, current and future performance of various companies.
• Product portfolio of various companies.
• Historical, current and future performance of various therapeutic classes.
• Projections for pipeline drugs.

Methodology & Information Sources:
To prepare this report, material was mined from both primary and secondary data sources. Primary information sources included data provided by pharmaceutical manufacturers, marketing strategists, scientists, doctors and product managers at leading pharmaceutical companies. Secondary data sources include both proprietary and public databases. These included company websites, annual reports, financial reports, 10K’s, government resources, books, magazines, white papers, journals, analyst reports and access to thousands of proprietary databases.

Table of Contents
1. Research Methodology & Definitions
2. Executive Summary
3. Dyslipidemia Prevalence & Patient Population
3.1 Prevalence of Dyslipidemia
3.2 Dyslipidemia Patient Pool
4. The Dyslipidemia Drugs Market Landscape
4.1 Current Trends & Forecast
4.1.1 Current Market Trends
4.1.2 Market Forecast
4.2 Share of Various Players & Drugs
4.2.1 Current Trends
4.2.2 Market Forecast
4.3 Performance of Various Therapeutic Classes
4.3.1 Statins
4.3.1.1 Current Market Trends
4.3.1.2 Sales of Various Molecules
4.3.1.3 Sales Forecast
4.3.2 Ion Exchange Resins
4.3.2.1 Current Market Trends
4.3.2.2 Sales of Various Molecules
4.3.2.3 Sales Forecast
4.3.3 Fibrates
4.3.3.1 Current Market Trends
4.3.3.2 Sales of Various Molecules
4.3.3.3 Sales Forecast
4.3.4 Other Cholesterol Triglyceride Regulators
4.3.4.1 Current Market Trends
4.3.4.2 Sales of Various Molecules
4.3.4.3 Sales Forecast
4.3.5 Other Classes
4.3.5.1 Current Market Trends
4.3.5.2 Sales of Various Molecules
4.3.5.3 Sales Forecast.

To buy the complete report or to get a free sample Call: +91-880-236-2536 (Asia), +1 206 204-1851 (America & Europe) - E: sales[.]expertmarketresearch.com or visit expertmarketresearch.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Reports Provide an Insight on the Potential of Dyslipidemia Drugs in Key Emerging Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Keshav Singh - ExpertMarketResearch.com 
+91 12 04155099 press[.]expertmarketresearch.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)